Interim Report for the period July – September 2022

Groundbreaking results for lecanemab in Phase 3 study in early Alzheimer's disease Events during the third quarter 2022 Lecanemab showed positive results in the pivotal Phase ...

BioArctic presents Nomination Committee

Stockholm, Sweden, October 18, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) Annual General Meeting on May 5, 2022, adopted an instruction regarding the appointment ...

Interim Report for the period April – June 2022

FDA grants priority review for lecanemab marketing application Events during the second quarter 2022 Eisai completed the rolling submission of lecanemab for treatment of early Alzheimer’s ...

Interim Report for the period January – March 2022

Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 Eisai commenced submission of lecanemab data in Japan for a prior ...

BioArctic publishes the Annual Report for 2021

Stockholm March 31, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Swedish version of the 2021 Annual Report has been published. ...

Proud partner of: